Andrew Haydon

15.0k total citations · 1 hit paper
143 papers, 3.1k citations indexed

About

Andrew Haydon is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Andrew Haydon has authored 143 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Oncology, 40 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Andrew Haydon's work include Cancer Immunotherapy and Biomarkers (40 papers), Melanoma and MAPK Pathways (32 papers) and Cutaneous Melanoma Detection and Management (32 papers). Andrew Haydon is often cited by papers focused on Cancer Immunotherapy and Biomarkers (40 papers), Melanoma and MAPK Pathways (32 papers) and Cutaneous Melanoma Detection and Management (32 papers). Andrew Haydon collaborates with scholars based in Australia, United States and United Kingdom. Andrew Haydon's co-authors include Graham G. Giles, Dallas R. English, Robert J. MacInnis, John L. Hopper, Dorota M. Gertig, Stuart K. Roberts, Helen Kavnoudias, Christine Ball, Peter Evans and Kenneth R. Thomson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Andrew Haydon

135 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Investigation of the Safety of Irreversible Electroporation in Humans

2011 355 citations Andrew Haydon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Haydon Australia	28	1.9k	751	464	398	351	143	3.1k
Nashat Gabrail United States	26	2.3k 1.2×	1.6k 2.1×	788 1.7×	251 0.6×	303 0.9×	154	4.4k
Lorin Roskos United States	34	1.5k 0.8×	1.0k 1.4×	478 1.0×	1.0k 2.6×	224 0.6×	127	4.0k
Jessica Wang‐Rodriguez United States	34	959 0.5×	2.0k 2.7×	634 1.4×	284 0.7×	333 0.9×	96	3.9k
Alessandro Ottaiano Italy	33	1.7k 0.9×	831 1.1×	569 1.2×	838 2.1×	72 0.2×	194	3.5k
Michael O. Idowu United States	35	1.1k 0.6×	1.1k 1.4×	360 0.8×	368 0.9×	309 0.9×	105	3.3k
Yuan Li Shen China	26	805 0.4×	657 0.9×	325 0.7×	333 0.8×	107 0.3×	75	2.6k
Svein Dueland Norway	40	2.9k 1.5×	1.0k 1.4×	601 1.3×	633 1.6×	220 0.6×	173	5.5k
Martin Schneider Germany	32	1.6k 0.8×	915 1.2×	661 1.4×	750 1.9×	336 1.0×	163	3.8k
Takahito Yagi Japan	30	1.1k 0.6×	783 1.0×	574 1.2×	320 0.8×	273 0.8×	256	3.7k
Jan S. Moreb United States	32	1.6k 0.8×	1.2k 1.6×	216 0.5×	347 0.9×	96 0.3×	123	3.3k

Countries citing papers authored by Andrew Haydon

Since Specialization

Citations

This map shows the geographic impact of Andrew Haydon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Haydon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Haydon more than expected).

Fields of papers citing papers by Andrew Haydon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Haydon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Haydon. The network helps show where Andrew Haydon may publish in the future.

Co-authorship network of co-authors of Andrew Haydon

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Haydon. A scholar is included among the top collaborators of Andrew Haydon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Haydon. Andrew Haydon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, Ryan J., J.C. Hassel, Teresa Amaral, et al.. (2025). 954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001). Annals of Oncology. 36. S585–S585.

Roy, Amitesh, Tim Bright, Nimit Singhal, et al.. (2024). Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.. Journal of Clinical Oncology. 42(16_suppl). 4086–4086. 1 indexed citations

Warner, Erica T., Galina Polekhina, Peter Gibbs, et al.. (2024). Cardiovascular disease and stroke following cancer and cancer treatment in older adults. Cancer. 130(23). 4138–4148. 2 indexed citations

Hauschild, Axel, Reinhard Dummer, Mario Santinami, et al.. (2024). Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.. Journal of Clinical Oncology. 42(16_suppl). 9500–9500. 2 indexed citations

Goodman, Rachel, Aleigha Lawless, Rachel Woodford, et al.. (2023). Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma. JAMA Network Open. 6(8). e2327145–e2327145. 30 indexed citations

Haydon, Andrew, Dirk Schadendorf, Reinhard Dummer, et al.. (2023). 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 34. S1707–S1708. 2 indexed citations

Warner, Erica T., John Zalcberg, Andrew Haydon, et al.. (2023). Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS). Cancers. 15(4). 1017–1017. 4 indexed citations

Bhave, Prachi, Angela Hong, Serigne Lo, et al.. (2023). Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer. 11(3). e006629–e006629. 14 indexed citations

Zalcberg, John, G. J. van Londen, Erica T. Warner, et al.. (2022). Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology. Current Oncology Reports. 24(11). 1579–1592. 23 indexed citations

10.

Orchard, Suzanne G., Nikki R. Adler, Rory Wolfe, et al.. (2022). Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. Cancer Epidemiology. 79. 102173–102173. 1 indexed citations

11.

Haydon, Andrew, Muhammad Alamgeer, Daniel Brungs, et al.. (2021). 1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]. Annals of Oncology. 32. S904–S904. 2 indexed citations

12.

Blinman, Prunella, Andrew Martin, Michael Jefford, et al.. (2020). Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum. 5(1). 4 indexed citations

13.

Reinwald, Simone, Mark Shackleton, Mark Voskoboynik, et al.. (2020). Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 108(1). 150–156. 12 indexed citations

14.

Tobin, Joshua W.D., Jane Royle, Robert M. Mason, et al.. (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. Blood. 130. 5338–5338. 4 indexed citations

15.

Haydon, Andrew. (2017). Student life - Where are all the male nursing students?. Nursing Standard. 31(33). 35–35. 3 indexed citations

16.

Blackley, Elizabeth F., et al.. (2017). Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma. Annals of Oncology. 28. v440–v440. 2 indexed citations

17.

Atkinson, Victoria, Georgina V. Long, Alexander M. Menzies, et al.. (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation‐positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology. 12(S7). 5–12. 18 indexed citations

18.

Walsh, Michael D., Mark Clendenning, Elizabeth Williamson, et al.. (2013). Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Modern Pathology. 26(12). 1642–1656. 122 indexed citations

19.

Kelsall, Helen L., Laura Baglietto, David C. Muller, et al.. (2008). The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study. Social Science & Medicine. 68(2). 290–297. 37 indexed citations

20.

Haydon, Andrew, Sherene Loi, D.S. Esmore, et al.. (2007). Incidence of Malignancies in Heart and/or Lung Transplant Recipients: A Single-Institution Experience. The Journal of Heart and Lung Transplantation. 26(8). 845–849. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact